Jafron Biomedical

National Congress of Nephrology of Ecuador Eleven internationally renowned brands participated in the highly successful National Nephrology Congress of Ecuador, where Jafron emerged as the highlight with its cutting-edge technology in extracorporeal blood purification. The conference brought together around 250 nephrology experts and scholars from both home and abroad, who praised Jafron's innovative medical device technology. Key highlights of Jafron at the conference included: • Booth Interaction: Jafron's expert team, alongside its local agent Nipro, provided detailed explanations of the working principles and clinical applications of hemoadsorption technology, building trust in the product's performance. • Academic Lecture: Dr. Darío Jiménez, President of the Ecuadorian Society of Nephrology, demonstrated the effectiveness of HA380 on hemoadsorption treatment process for Rhabdomyolysis. • Technical Workshop: The DPMAS technical workshop, co-hosted by Mexican Nursing Specialist Diego Huerta and Jafron's Latin American academic manager Emilben Zambrano, showcased the ease of operation of Jafron's products. Jafron's presentations not only enhanced the academic value of the conference but also reinforced its leading position in the field of extracorporeal blood purification. We look forward to continuing to showcase our innovative technologies at more high-level academic events in the future, contributing to the advancement of global nephrology. Thank you to everyone who made this event a success! 🙌 #Nephrology #MedicalInnovation #HealthCare #Hemoadsorption

We are delighted to announce the success of our recent nationwide clinical discussion series on Hemoadsorption. Over the past few weeks, Jafron hosted seven sessions at various hospitals across India, exploring Hemoadsorption as an innovative approach in blood purification. The overwhelmingly positive feedback from participants has been deeply encouraging. These sessions covered critical topics, including the use of the sodium dithionite test in paraquat poisoning and the role of adsorption in renal replacement therapy (RRT). This has fostered a deeper understanding among healthcare professionals. At Jafron, we are steadfast in our commitment to advancing clinical excellence in blood purification. Join us as we continue to explore breakthroughs and innovations that promise to transform patient care.

Professor Eladio Miguel Peñaranda presented his findings on the use of HA130 alongside hemodialysis in the Philippines during the 61st ERA Congress in Stockholm, Sweden. The studies focused on MHD patients undergoing three sessions per week of HDF with HA, detailing patient selection, treatment duration, biochemical marker assessments, and albumin levels. The research demonstrated positive outcomes, including reduced inflammatory markers, improved physical health, increased energy levels, and enhanced emotional stability, contributing to an overall sense of well-being among the patients. For more information, please view the video presentation at: https://lnkd.in/gUjakfHC. #Jafron #hemoadsorption

Professor Dimitrios Petras shared his insights on hemoadsorption using low flux dialysis at the 61st ERA Congress in Stockholm, Sweden. This treatment is utilized on 60% of dialysis patients in Greece. He discussed various studies, challenges, and future perspectives in this field. Professor Petras concluded that hemoadsorption shows greater viability in patients with low blood flow resulting from poor vascular access. Moreover, hemoadsorption therapy have improved its biocompatibility, reducing adverse reactions over time.  For further details, visit link to the video presentation: https://lnkd.in/gSYH-d_m #hemoadsorption #Jafron

At the 61st ERA Congress in Stockholm, Sweden, Professor Claudio Ronco from Italy delivered a lecture during Jafron industry symposium session. He emphasized that the retention of uremic solutes exposes end-stage kidney disease (ESKD) patients to significant inflammation and cardiovascular disease risks, which are interconnected in a detrimental cycle. Specific molecules are associated with distinct symptoms and complications, impacting major outcomes such as survival. Therefore, the classification of uremic toxins is crucial. Professor Ronco introduced hemoadsorption therapy as a potential solution during blood purification processes. He concluded that this therapy could effectively remove specific uremic products, potentially enhancing quality of life, reducing cardiovascular complications, and significantly improving conditions like microinflammation and renal anemia. For further insights, refer to the video below. #ERA #Jafron #hemoadsorption

On June 11, 2024, during the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology 2024, Professor Rinaldo Bellomo announced the global selection results for the first round of applications for the 'SAILING Program'. The first round of the “SAILING Program” attracted 58 study protocols from various countries, including China, Italy, Portugal, Switzerland, Brazil, Russia, India, Iran, the Philippines, Thailand, Turkey, and Oman. Following rigorous review and selection by the Global Academic Committee, 17 studies have been awarded. These studies encompass a broad spectrum of applications for hemoadsorption technology, addressing areas such as nephrology, sepsis, drug intoxication, cardiac surgery, as well as exploring innovative fields like neurological disorders, drug-induced liver injury, and cytokine adsorptionps. All awarded studies are required to revise and finalize their protocols, with the completed versions due for submission to the program email SAILING@jafron.com by July 31, 2024.   Announcement of the Second Round for Applications To further advance clinical studies in hemoadsorption and related extracorporeal blood purification fields, the “SAILING Program” will continue its funding initiative in 2024. During the 42nd Vicenza Course, Professor Bellomo announced the commencement of the second round for applications.   Application Period: June 11, 2024 - November 29, 2024 Study Duration: two years (2025-2026) Application Method: Submit an initial proposal to the program email SAILING@jafron.com. Learn more: https://lnkd.in/ggkb7QyB #Jafron #Sailing

Welcome to our Spanish webinar on "Efficacy of hemoadsorption with HA130 in the dialytic phase of chronic kidney disease." The webinar will take place next Thursday, June 27th, at 7 PM Ecuadorian time. We kindly request your pre-registration and participation by scanning the attached poster code beforehand. Bienvenidos a nuestro webinar en español sobre "Eficacia de la hemoadsorción con HA130 en la fase dialítica de la enfermedad renal crónica". Se llevará a cabo el próximo jueves 27 de junio a las 7 PM, hora de Ecuador. Agradecemos su preinscripción y participación escaneando el código adjunto del póster. #Jafron #HA130 #hemoadsorción #Webinar

In the first half of June, Jafron's team organized Hemoadsorption Days, Hemoadsorption Weeks, and Nursing Weeks across multiple locations including Czechia, Turkey, and Brazil. These events featured a diverse program of academic lectures, workshops, and interactive discussions. International experts shared their insights and experiences with Jafron cartridges across various disciplines: Prof. Antoine Schneider from Switzerland discussed "Hemoadsorption and drug pharmacokinetics." Prof. Fethi Gul from Turkey contributed valuable insights into “Immune system and blood purification”. Dr. Petr Piza from Czechia provided expertise on DPMAS. Dr. Garcia Nogueira and Dr. Pena Esteves from Portugal delivered impressive lectures on Hemoadsorption in the ICU and during CPB. The overwhelmingly positive feedback from delegates representing hundreds of hospitals across Europe, Asia, and Latin America underscores the significant impact of these events on advancing knowledge and practices in Hemoadsorption. #Adsorption #Hemoadsorption #Jafron

In early June, Jafron collaborated with our global business partners to participate in a series of exhibitions and academic forums worldwide: ESICM Lives Forum Conference in Istanbul, Turkey Congress of the Spanish Society of Cardiovascular and Endovascular Surgery in Madrid, Spain National Conference on Clinical Toxicology in Vijayawada, India Congress of the Portuguese Society of Intensive Care in Porto, Portugal Colombian National Congress of Critical Care held in Pereira, Colombia. During these events, Jafron products were prominently featured in presentations by esteemed experts, and the showcase of Jafron's cartridges portfolio, F20 machine, and combined applications garnered significant interest and attention. Jafron achieved a notable milestone by successfully demonstrating the versatility of its hemoadsorption portfolio and its compatibility with other common blood purification equipment available on the market. These engagements underscore Jafron's commitment to advancing the field of adsorption and hemoadsorption. #Hemoadsorption #Jafron

The 42nd Vicenza Course on AKI-CRRT-ECOS, held in Vicenza, Italy from June 11th to 13th, 2024, and hosted by the International Kidney Institute of Vicenza (IRRIV), concluded with great success. During this prestigious gathering, the Jafron International team made a significant impact. Professors Claudio Ronco and Rinaldo Bellomo led enlightening discussions on the expert consensus of the Acute Disease Quality Initiative (ADQI) during Jafron’s "Meet the Expert" session, shedding light on Jafron's groundbreaking SAILING project. Professor Bellomo from Australia announced the preliminary results of the SAILING program worldwide. A total of 17 studies were selected from 58 applications in the first round, generating immense interest among experts worldwide who eagerly anticipate the project's outcomes and future engagements with Jafron. The Jafron satellite symposium on June 12th featured distinguished experts such as Claudio Ronco, Grasselli Giacomo, Lavinia Ionescu, and Ranistha Ratanarat, engaging in pioneering dialogues under the theme "Master the Acute Phase." Covering topics like "Innovative Breakthroughs in Pediatrics" and "Advanced Liver Support Therapy," the symposium captivated a full house with groundbreaking insights on Hemoadsorption treatments. The enthusiastic Q&A session underscored the immense interest and potential for transformative advancements in these critical areas. Furthermore, the international debut of the Jafron pHA130 cartridge showcased its remarkable adsorption capabilities, sparking passionate discussions among attendees. Additionally, Portuguese experts shared their successful utilization of HA380 in treating myeloma patients, further enriching the exchange of knowledge and experiences at the conference. #Jafron #Vicenza #Hemoadsorption